Further research has confirmed the efficacy of CD47 blockade agents and CCR2 inhibitors in slowing tumor growth and modulating the tumor microenvironment (Wu et al., 2020; Kruglov et al., 2022). The gene discussed is CD47; the disease is neoplasm.